-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 HFCZWaF747yKysnBMT07xGCFD8K6MrCyVJ5Otr8f1K0yCm992ZDMzJ2X9pYkltV/
 e1Y1wYmwSNH7B5pRLuEfew==

<SEC-DOCUMENT>0001193125-07-148423.txt : 20070702
<SEC-HEADER>0001193125-07-148423.hdr.sgml : 20070702
<ACCEPTANCE-DATETIME>20070702171853
ACCESSION NUMBER:		0001193125-07-148423
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20070702
DATE AS OF CHANGE:		20070702
EFFECTIVENESS DATE:		20070702

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CRYO CELL INTERNATIONAL INC
		CENTRAL INDEX KEY:			0000862692
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-SERVICES, NEC [8900]
		IRS NUMBER:				223023093
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1130

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-23386
		FILM NUMBER:		07956383

	BUSINESS ADDRESS:	
		STREET 1:		3165 MCMULLEN BOOTH RD
		STREET 2:		BLDG B
		CITY:			CLEARWATER
		STATE:			FL
		ZIP:			33761
		BUSINESS PHONE:		7277230333

	MAIL ADDRESS:	
		STREET 1:		3165 MCMULLEN BOOTH RD
		STREET 2:		BLDG. B
		CITY:			CLEARWATER
		STATE:			FL
		ZIP:			33761
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>ddefa14a.htm
<DESCRIPTION>NOTICE & PROXY
<TEXT>
<HTML><HEAD>
<TITLE>Notice &amp; Proxy</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="4"><B>UNITED STATES </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="4"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>WASHINGTON, D.C. 20549 </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>SCHEDULE 14A </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>(RULE 14A-101)
</B></FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>Proxy Statement Pursuant to Section 14(a) of the </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="3"><B>Securities Exchange Act of 1934 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT FACE="Times New Roman" SIZE="2">Filed by the Registrant: <FONT FACE="WINGDINGS">&#120;</FONT>
&nbsp;&nbsp;Filed by a Party other than the Registrant: </FONT><FONT FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2"></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT FACE="Times New Roman" SIZE="2">Check the appropriate box: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Preliminary Proxy Statement </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</B> </FONT></TD></TR></TABLE> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Definitive Proxy Statement </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#120;</FONT>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Definitive Additional Materials </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Soliciting Material Pursuant to Rule 14a-11(c) or Rule 14a-12 </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>CRYO-CELL INTERNATIONAL, INC. </B></FONT></P><HR SIZE="1" NOSHADE COLOR="#000000"
ALIGN="left"> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT FACE="Times New Roman" SIZE="2">Payment of Filing Fee (Check the appropriate
box): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#120;</FONT>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">No fee required. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(1)&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Title of each class of securities to which transaction applies: </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE WIDTH="99%">
<TR>
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="92%"><HR SIZE="1" NOSHADE COLOR="#000000" ALIGN="left"></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(2)&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Aggregate number of securities to which transaction applies: </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE WIDTH="99%">
<TR>
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="92%"><HR SIZE="1" NOSHADE COLOR="#000000" ALIGN="left"></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(3)&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was
determined): </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE WIDTH="99%">
<TR>
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="92%"><HR SIZE="1" NOSHADE COLOR="#000000" ALIGN="left"></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(4)&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Proposed maximum aggregate value of transaction: </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE WIDTH="99%">
<TR>
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="92%"><HR SIZE="1" NOSHADE COLOR="#000000" ALIGN="left"></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(5)&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Total fee paid: </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE WIDTH="99%">
<TR>
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="92%"><HR SIZE="1" NOSHADE COLOR="#000000" ALIGN="left"></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Fee paid previously with preliminary materials. </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the
previous filing by registration statement number, or the form or schedule and the date of its filing. </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(1)&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Amount previously paid: </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE WIDTH="99%">
<TR>
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="92%"><HR SIZE="1" NOSHADE COLOR="#000000" ALIGN="left"></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(2)&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Form, schedule or registration statement no.: </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE WIDTH="99%">
<TR>
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="92%"><HR SIZE="1" NOSHADE COLOR="#000000" ALIGN="left"></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(3)&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Filing party: </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE WIDTH="99%">
<TR>
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="92%"><HR SIZE="1" NOSHADE COLOR="#000000" ALIGN="left"></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(4)&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Date filed: </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE WIDTH="99%">
<TR>
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="92%"><HR SIZE="1" NOSHADE COLOR="#000000" ALIGN="left"></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>

<IMG SRC="g95180image001.jpg" ALT="LOGO"> </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>GLASS, LEWIS RECOMMENDS THAT CRYO-CELL SHAREHOLDERS VOTE </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B><U>FOR</U> ALL MANAGEMENT NOMINEES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="2"><B><I>Independent Report Concludes Company Has Performed Well Under Current Leadership </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Oldsmar, Fla. &#150; July&nbsp;2, 2007 &#150;
Cryo-Cell International Inc. (OTC Bulletin Board: CCEL),</B> announced today that Glass, Lewis&nbsp;&amp; Co., one of the nation&#146;s leading independent proxy advisory firms, recommended that Cryo-Cell shareholders vote unanimously <B>FOR </B>all
Cryo-Cell nominees on the Company&#146;s <B>WHITE </B>proxy card at the Company&#146;s July&nbsp;16, 2007 Annual Meeting, citing their independent view that the Company has performed well under its current leadership. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">&#147;We are very pleased that Glass Lewis, a well-respected independent advisor, has recommended a vote for Cryo-Cell&#146;s current highly experienced directors,&#148;
said Mercedes Walton, Cryo-Cell&#146;s Chairman and CEO. &#147;We believe this recommendation supports our view that current management is taking the Company in the right direction, and that the inexperienced dissident slate of nominees has not
stated a case for its attempt to take control of the Board without being willing to pay a premium to Cryo-Cell&#146;s shareholders, and without a credible plan for the future success of the Company.&#148; </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">In recommending that Cryo-Cell shareholders vote FOR Cryo-Cell&#146;s incumbent directors and AGAINST the nominees of David Portnoy and his associates, the Glass Lewis
report states*: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><I>&#147;In our view, the Company has performed well under its current leadership. We note that total revenue has grown considerably since
fiscal year 2003. More recently, while SG&amp;A expense as a percentage of sales has increased, the Company&#146;s margin appears in line with that of Viacell Inc., the Company&#146;s primary publicly traded competitor. </I></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B></B><I>&#147;In light of Cryo-Cell&#146;s financial performance over the past several years, we believe the Dissidents&#146; stated recommendations (to dramatically
reduce SG&amp;A expenses, redirect marketing resources toward doctors&#146; offices, consider a share repurchase program, and cut directors&#146; fees by 50%) do not constitute a substantive plan for improvement. Moreover, we believe that the
Portnoy Group&#146;s demand for control of the Company&#146;s board appears out of line to the Dissidents&#146; ownership of only 13% of the Company&#146;s outstanding common stock. In our view, any dissident shareholder seeking to take over a board
should pay a premium for the privilege through a buyout offer to shareholders.&#148;</I><B> </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">The Company urges shareholders to vote <B>FOR</B> the
Board&#146;s nominees by signing, dating and returning the <B>WHITE </B>proxy card and to discard the gold proxy card of the dissident group. Any shareholders requiring assistance may contact Georgeson Inc., which is providing Cryo-Cell with proxy
solicitation services, at (888)&nbsp;605-7511. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><I>*Permission to use quotations was neither sought nor obtained. </I></FONT>
</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px">
<FONT FACE="Times New Roman" SIZE="2"><B>About Cryo-Cell International, Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Based in Oldsmar,
Florida, with over 135,000 clients worldwide, Cryo-Cell is one of the largest and most established family cord blood banks. ISO 9001:2000 certified and accredited by the AABB, Cryo-Cell operates in a state-of-the-art Good Manufacturing Practice and
Good Tissue Practice (cGMP/cGTP)-compliant facility. Cryo-Cell is a publicly traded company. OTC Bulletin Board Symbol: CCEL. Expectant parents or healthcare professionals may call 1-800-STOR-CELL (1-800-786-7235) or visit www.cryo-cell.com.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Forward-Looking Statement </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Statements wherein the
terms &#147;believes&#148;, &#147;intends&#148;, &#147;projects&#148; or &#147;expects&#148; as used are intended to reflect &#147;forward-looking statements&#148; of the Company. The information contained herein is subject to various risks,
uncertainties and other factors that could cause actual results to differ materially from the results anticipated in such forward-looking statements or paragraphs, many of which are outside the control of the Company. These uncertainties and other
factors include the uncertainty of market acceptance of any potential service offerings relating to types of stem cells other than cord blood stem cells, given that such new stem cells have not yet been used in human therapies, and treatment
applications using such stem cells are subject to further research; the need to complete certain developments, including completion of clinical validation and testing, before any such process can be commercialized, and the Company&#146;s development
of its final business and economic model in offering any such service; any adverse effect or limitations caused by recent increases in government regulation of stem cell storage facilities; any increased competition in our business; any decrease or
slowdown in the number of people seeking to store umbilical cord blood stem cells or decrease in the number of people paying annual storage fees; any adverse impacts on our revenue or operating margins due to the costs associated with increased
growth in our business, including the possibility of unanticipated costs relating to the operation of our new facility; any technological breakthrough or medical breakthrough that would render the Company&#146;s business of stem cell preservation
obsolete; any material failure or malfunction in our storage facilities; any natural disaster such as a tornado, other disaster (fire) or act of terrorism that adversely affects stored specimens; the costs associated with defending or prosecuting
litigation matters and any material adverse result from such matters; decreases in asset valuations; any continued negative effect from adverse publicity in the past year regarding the Company&#146;s business operations; any negative consequences
resulting from deriving, shipping and storing specimens at a second location; and other risks and uncertainties. The foregoing list is not exhaustive, and the Company disclaims any obligations to subsequently revise any forward-looking statements to
reflect events or circumstances after the date of such statements. Readers should carefully review the risk factors described in other documents the Company files from time to time with the Securities and Exchange Commission, including the most
recent Annual Report on Form 10-KSB, Quarterly Reports on Form 10-QSB and any Current Reports on Form 8-K filed by the Company. </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g95180image001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g95180image001.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`*P"3`P$1``(1`0,1`?_$`,$```("`P`#````````
M``````@)``<%!@H#!`L!``,!`0$!``,````````````%!@0"`P<!"`D0```&
M`0$'`@(%!@D-`0````$"`P0%!@<(`!$2$Q05%A<)(1A!(C(C)#%#Q"8W&6$S
M-"4UMG>'.%-DA)1%U39VEB<H2%EI$0`!`@0#!0,'"0<"!P`````!`@,`$00%
M(3$205%A@09QD1.AL<$B,C,50E)R(W,4-18'X?%BPE.#T]&2\++B0S145?_:
M``P#`0`"$0,1`#\`ZL]>NN:XX8L])TT::*RWR'JLRV5`M?BE$4W\91(A^=PB
MUL$RS,LBW<2+H&BZS9%RHDT;M6RKQV8&Y"D7>6JUMU+:JVM.B@;S/SCN'IEC
M,R&.4[>KP[2.(M]O3XER=R&82-YXYRG@`"3AG0T+[2M^S,V;VS6OJXS'D6]2
M"0.7E=HLRSB:C6UU1%48Z+5EXN1;.$FAS<(&:QL:AO#ZJ6[<(ZE7]JF/AVVG
M;0T-JA,GMD1Y28Q(Z9?JQXMWJG7'CF$F21P$QY@(P5S]N+4MI0B7V1]`^IK)
MTA(5Y,TJ\P?D=U'3L1<FC(IEEXZ,*5LSKCZ263`P)-7+!$ZYAX4WB*@E$>V[
MQ15Z@S=64`'#6G`CMV\P>1CAVPW"VH+]EJ'"I./AJD0K@,A/@1S$'1[?^MJ(
MUH8LDIB0AT:AEC'\BA7,J4I(7`(1TJLFL+&;B"/=[Y."G>D7!-)<1<-'+==L
MH)Q2!517=K8JVOA(.JG6)I5PW'B/*)&'%DNZ;M3%:AHJ4&2T[CO'`\<001LG
M!Y[*H=1-B")L01-B")L01-B"->MMKKM$J]ANENEV<#5JK#2-@L$T_4Y3.+AX
MEJJ]?O7!P`QN6@V1,;<4!,80W%`1$`V[;;6ZL-MB:U&0&\F.'7&V6U.ND);2
M"23L`SA#U>R1K1]U.UV9SAN]2VD_1K79AW7DKC&M5BY$R,JV-P.4TG+9PS?+
M/U&RP'<-FSQE&QI3E164>."G*%2MFVV)"14I#]Q(G(^RG_C?(D[)"(QNHNW4
MCJC2+--:DF6H>TKTSW@$`9&9BUC>R'A8C;N#34'J3;7P`!=.Z^55XZY9(/B#
MX69*VB['Z_QX0>%4W?#F;_CMX?F:IGI++/A?-D?]?1&G\H4@&H/U'C?.U#/?
MEZ8J^/U!:K_;,S%2<8ZMKTXS[I7R+)=FIV<'S58;53%2'32-WEVJ=U)JFAD%
M$UGT<]7?&,Q`[A@Y-R5FVWL:2@O5.IZWI\*O0)E&P]FS'81+'`C&<9DUUSZ?
MJD4]S7X]M<,DN;4]NW#:"3ABDX$0_=!=!T@BY;+).&SA)-=NX04(JBN@L0%$
MED54Q,11)5,P&*8!$!`=X;2A!!D<XM001,91Y=B/S$V((3UH+R=D>XZW_<=J
M5MO=LLM6HV1VC&EUV<G9"2AJHR-;+TV,TKT<Z64;13<S=FD02(E*'"F4/R`&
MU#=6&6[91N-H2E:D8D"1."<]\2UEJ*AV[U[3JU*;0Y)())"?65D-D<[WS=ZJ
MN7O^8[->_P!5.W;_`%&LW\@ZKAZ+^D/Y-P_#@^SM7?<*'^BW[N?LB(7XI<I?
M^0][WYQRW9P[SVM6[?4=JKUG:UK*F,A)+W%+'N.%790<!!UYZ11=5./44XA0
M4;5"(A69#$W"")U@W[E3`,U?":.@IK:C`:=2N)_>5'NBOZ<`K[E5W=S%6O2G
M@#_TA([X?5M*Q:1-B"%=Y&TQ5?1W'ZW=9V$K7;87)5\Q1D"SN*[(A6I&@0MG
M:D&V-IV)KYJ\DLHY1G&JZH)NG#E$>N7*)!`P<+QFM7<54UMJ4I+*'$B>.HC*
M1,]V[<(G'[<W:DUEVHU*%0MI1D9%(/M3`EOWDYF!+QGKLUJZF<8XCQ3I9A:K
M;\ZFQ[%6C47GVVQ<;&8]QG)STG*=FKS>+:LTX$UL<1#5-=5`C5X)$QX2-%#`
MLHCO>M=MHGG'ZXJ32ZR&VP9J5("9GG*?$=N4UM/>;O<*=JFMP2NMT3=<4`$H
M))D)9:I;)'LSEF<YY>U^Z$:EINR3G+-=:RU4)+-4A6]0!*]2Z\6.\2G'$=(U
MI*,E%JE`2\2Y:PC*83$R":29G"+<-YN88!YI:>U71QYFE:+;@:FW,F<QG/$@
MXRSV3CJLJKW9FJ>HK'DNM%TAV21+29$2.D$8:N<H>LR>M)%FTD&#A%XQ?MD'
MK)VW4*JW=-'21%VSA!4@B51%=$X&*8/@)1`=I<@@R.8BR!"@%)Q!A8ON':F\
MNXRN&F73_IULL56,OYZR*5*1GI*%A["C6,;Q!2-9Z8>1\ZS?1S=H560%V=R<
MF]-O%N-P@&\=G=HHJ=]M^KK$E5.TC``D34<AACPEQ$3M]N-53NT]#0*":IYS
M$D`R0,SC,;9SW`P-S74UK+]P+)-SI>BFTPN$M.F-Y(U9G]1UB@&TS8KU+(E)
MQJUABZ8JM4!?HE!TW:M46ZJ315-9RZ0%=)MML-%;K2RERY)+M8L3#8,@D<?,
M29XX`&4XP"XW:]U"V;0H,T#9D72)E1X#CF``,,21,"-IN6!?=/TZP[K)6*M7
MB&J4:\W-*SV(LD8_CXYU9HYD'/>LJVL@^D'3B1.W3-RT$'T<X5'ZJ1SJ"5,_
MFW56.L5X+]/X$\`M*LNW]QCU=HNI*!!J*:J^\Z1,H6D"8&[$X\P8%+75[@T7
MJD]OFAM<?(+U.[9AS'$8KR?1U'G.>UZ2K#'R=_!"H)&[EY"3\MVE5JL9-,5V
MISI*%*J15,K"U6==%=EJ=]9IMLJ2J6!GA/M`G/<>$++S?47&QH#/JO.NA"T[
MB!.7$$Z9;QAG.'^X&Q)`8(PUC;$-9;(MHJA5*(@=Z)0+UTB@V*I-RZX_G'DW
M,JN':YQ^)UEC#].TG55"ZJI74+]I:B>6P<AA%M14J**D;I6Q)*$@<]IYF9BV
M]L\:H'#53I?QWJ\Q(^P_DM>;CX-S-0MA9S%:6CF\_#RT(X,HBZC'$K&RS)(S
MIFNNT6XD#\39PH4-PB`ALH:YZWU`J&9%4B)'(@[Y$=L8+E;F+I2FEJ-002#,
M2F"-TP>S+(P,NJ[4Y'^WMI^Q'C>DL9?+^7YN/@<2X3K$\IULU9W5?CXR"2L5
MI"#:L%7Z3(%F:2B31)!5^^<I(IBGQG53VT%$;M5N/.D-TX)6LC(3F9"?//(0
MNN5Q38Z%JG:!=JB`AL',R`$S+.6&69(&&<4-7=*?NE9-ATKSD_7H.'+E*MR/
MV^-:!C^$E:Y6C*E!9"(E'K1S#-7"[4=R:P)E?E`0$.H7^T;6NOL;*O"8I?$;
M'RE*()XC/T=@C&W;>HZA'C5-;X3IQT)2"!P.7I[3&P:==6VH[#VI"+T7:[2U
MV7M5U9G>8/SO5V:,5!Y&*@"Q4X>5:-VL>Q"1?=*=))0C9HX2>E!NNDH+ANX/
MQ64%'449N5KF&T^V@XE/$<._#$9$1W07.OI:\6F\Z2ZL?5N#`+X'+'D#/`Y@
MQH?MS_X__='_`+46?]<LA;>MX_":'[/T)CQL/XW<?M?YE1S'_FO[X/TO:S_Q
M1\\V?W8Z3/8WXZ?7M6&%IHH-+?CK,[(\PP5$$W14U8A>JF5Y!MQP33DJ8X*(
M[MP"8-_Y0VC^I_K%L5*?=K;P[Y^90B_Z/^J14TB\'6W<>Z7G28?%M+19Q-B"
M%?:S-5V(K/2=9VD^%>3[S+='TRY&N%D0+`N@K3"(&EQ\AN-8^(69GO)LS,O)
MW<7,4$OY0'9W;:&H0[35ZI"G4^E(QQG,C+D8G;M<J5QFKMB"HU2*=2CA@!I!
MSYB/>]H:A5^EZ#\0RD.R10D\AGM-[M#TI"@O)3+^SRT4W4<*``'4!E!Q#1JF
M`B(%(B&[Z=OQU`ZMRZN)4?51)(X"0/G),==+LH:LK2DCUG)J/$DD>8`03NL+
M`S+4OIMRSAQPDB:1M%7=+55PN5,0872%,2:J+T#J?Q)"3S!`BI@$!%`ZA?R&
M';%;JHT58W4#V4JQ^B<#Y(872B%PH':0^TI.'!0Q3Y1W0,GM-YT>YCTBU:NV
M958N0<%R+W#%T8O3[Y)N:I%23K2KQ(WWI#C656S8XF^)G+1;Z0';;?J44UP4
MM'N71K3NQS\N/,0NZ9K#5VM*'/?LDMJ!S]7+R2':#"O,[VJ7SAE?W+-7,4N=
M>I:8L,2>F##TD14QT$+':E34V\3T.L3Z@K-&,S-G`Y!`03ET#;_@`[/*5M-,
MQ16]7O'W`XOL&*0>Y/<8G:UQ594W"Z)]U3M%E':?541R*O\`<(;O[7=(@Z-H
M2T]-H5L@B:R5`UWF5T2`0[^<MTB]F'KER8-XJ*H)KIMBB/Q*BW(7\A0VG[XZ
MIVZ/%7R5:1V`2_;%1TZRAFS,!'RD:CQ*C,_Z<H/W93#N$U*X"P+&SV=1DZS6
M*C(/LD66\-X-:#3>=;9WDHZ=EF2'>E<&1<)KN3*M2H\LB*:@%2*!!#;^._Z@
M?JOU=U!^I'6URZVZXO73'4O3=0XQ:;=3J=0WX36OP5A*'&T.>*`DE6@^)F2J
M<?LY8.B[#16*TLV2R4MSM]R2%UKZDH44K405@E0)1IFK:-,L)2ALF/)65G:+
M4)F<3(E+RE=B'[\$Q(8AW#IDBJ=8O+WI@#CB!3<'P+Q;OHV_J+^DMZZEZC_3
M*PW[K)@TW5-7:J=VI;(TE+JVTE1*?D*5[91\@J*=D?K_`-34MMH>H:VCM"_$
MMC52XEI6<T!1`QV@9`[93VQN.WT.$<5;FK,5(P!B^W9?R,[>L:726+=_-N(Y
MBK)R`).Y%G%-4F4>B(+/'+A^_23(0OQ$3;>]-3NU;Z:=F1<4<)X<8S5=4S14
MZJI\D-($S+$YRRYQSM9SU31N1_<DTV9WI6(LG9[IM8T_1MYQ=C2KP*R-U?KS
MQKT=.UC`.DG*C8D4\43>&,)1,!6K<^_<4NU?2T*F;,]2N.(:=4Z4J43ZN&G"
M?'+F8A:RY)?O]/6M-./,I8"D(`]8SU>M+AGR$,)_>7YG_P#FEK(_Z7'_`'5L
MH^"T_P#[M-W_`+8>?F"J_P#GU?\`M_9`(:W,T:@M5JV`IJEZ"=5F.+[A#+<3
M?8:US='DGR98LBC1>1BD2Q44#I-1Q)Q3!QQ&,"8`U$!^(ALUME-24`=2[5,+
M9=;*2`H9[#B=Q(YPFN]76W(L+9HJEMYET*"BDY;1@-X!Y03WMR&XM?GNAGX1
M*)\FQYQ(;[1!/;\@F$A@^@Q1'</\(;8;Q^%4/T/0F&-A_&KC]I_,J.9#\U_?
M!^E[6?\`BCYYL_NQT>:J(.^>W?K25UW42KRELT\9I;H5_4;7X)+F.:W*NU&2
M3J=.F800;]Q>LD)-BZ5,F@:2ZMHJHB#Q(QI"A4U=[;\+=4$U;6+9.T;O01ND
M=D7MR0]8KM\99254+V#H&P[^<@0=\P93$."PUJ3P9J`K+*UXER95+='O&Z:Z
MK-I*MD)Z).8I1.SG:Z[40FH5\@8>$Z3E!,P"'PWAN$9^IHJJD66ZA"DJ'#`]
MAR,5-)<*.M;#M,XE22-^([1F.<5?JHUP8#TFTJ6L5\N4-)6M)BX/6<:0DJQ>
M7.TR8)CTC1*.1465B(TZPAU$@[*FU;)<1A,8_"F?VH;955[H0TDAN>*B,`/2
M>`QC/<KQ16QDK>6"[+!`(U$]FP<3@(3[A#!V3'&D'W"=;^=XU:(R?JBQ)DE_
M7H9TW69NH?'BL3)2Y%^B<@5RP8S[L&I&+=4I5"QD8U4$/O@`**IJF1<*2V4I
MFPPXF9WJG+R8SXDQ+4='4&U5UWK1*HJ6ED#<F1/*>$AN`WPT7VMO\`6FC_DN
M4_KC9=D=\_%GOI#S"*+IS\$I_H'_`)C!^[*8=QSB9XRJ\]LC61JLGHYN[;X_
MU8X.L&3<=-V:)CL6.>8SK&[0#III\I%).T2#]PXW``$;R:&_X`&UC2L"]6YA
M!]]3NA*OH']DNXQ!5M2KIZZU*TS\"I9*T<'!/TS[Q!SZ6=%B3+VT5M/EG`6-
MRSSCFSVR]23P#F<MK]DV.[I&.Y'ZHK'<U=/MJ"I1WF$[(WTCLKKKD3>OO:,6
MVE@)'\*<#WX]\.;;:0GI_P"XNX.O-E2C_$L3$^S`<HJSVH]2\;6Z*YT/9Q=M
ML>Z@,`SL[5(ZL65=*,5ME8-*N9%D%?<.U$T99]"JOSH@BD(F7C>E=(@HDH<R
M?O?J(K=^)TOKTCH!)&,C+;NGYYB,W35P2VR;/6$-UK"BD`X3$YB6^7E$B,(:
M9FK.F+-/=#F<C99MT75*Y#,UW(=6Y0[I,N4B"9&(KL4*I'DY-/E-R:#9`ICF
M,.\>$H&,".FI7ZMT,TZ2I9/(<2=@BCJZRFH62_4J"6P.9X`;2=T)$TH:<LGZ
MV<1:TL[WZ9M.-SZL+!(.\!-SR\N@C3FL0]7=L+0S;(K$$D/+J-6$(Y5;@4TC
M&L'&[B363,.7J?HK]/*[J2W7R\V2T7#J*VI2$U3](PZ^D#%*4NK05#025H!/
MJ*(*9&%%@N/4SMHN#-+75E);[@3)I#SB&R,<5(2H`A6"%8>LD&<P8LSV_P#7
M4UQ"Q;Z(]:3H,/9DPZ*5.J5AO#GH*W<*HT,#>ML%+*[,6,1>,(\"(Q[Q10C&
M5CB(G25%<%"#57>V&I5\4MWUM.[ZR@,P=IEGCM&8,]D+[)>!2I%GNWU54UZJ
M2K`*2,A/+`9'(B4C.'4+6^IMXD\^O:*ZC!)M^K/-+3<:G$D:@'$+D\D=R5F5
MOP_'C$_#N^G::#;A5H"3JW2,XK2ZT$ZRI.C?,2[X0%KSU%K^X%D*EZ!](C\M
MTAY"U1T_F?*4."KJFQL9`.BG(1&51#I7];K#DPOG;LHF0>R"#1HT,JH8X;5=
MJH_A+*KK<!I4$R0DYS/#><@-@F3$5>J\WM]%DM9UI*@7%CV0!QV@9D[3("<;
M)K-I`:"]26BG5Q48&0?83QE1X/37DL(UH+MY#56/CY*`AY%VDD!$SN9&!GG!
MT!'A*K(1J:0F`[@G%Q;7/BM'4T#A`J5J+B>).)\H'(\([NS/P6OI+HTDFD;0
M&ERV``@'F">8`VP\FB9#HN3ZI%7G'ML@KC49MFD_C9^`D6[^/7;K)%5#C51.
M)FKA(IMRJ*H$61.`D4*4Q1`)AUEUAPM/)*7!F#%BR^S4-AYA25M$3!!F(5[J
M1UJ9!MFK'!&D;1K<8&3M+NS&EM0EK8PD-=86FT9DHS4E(H[QV5U&M9>/B2N5
MW1DS<:#D[-L)@66,F#RCMK+=`[<+BDAO3)L3*25;#OE.4N$SD(G;A=WW;FS:
M[4M)=*INJ`"@E.T;I@3GN,AF916OMS_X_P#W1_[467]<LA;>UX_":'[/T)C/
M8?QNX_:_S*CF/_-?WP?I>UG_`(H^>;/[L?0ADHV.F(][$R[!E*Q<DU792,;)
M-4'T>_9.4S(N6CUFY35;NFKA(XE.F<IB'*(@("&WR<$I(4DD*&V/N*DI6DI6
M`4D8@X@PL;(GL[:&K].+V%E0K)C:0=*'5<IXPN,G6HM0ZAC'/R85T67B(U,3
M&'[MHBW2#Z"AL[9ZANC2=!6E8_B`)[\#WQ//]+6=]>L(4VH_,40.[$#E&TX8
M]J315A.PM;=%XV>7JT,'*;R.F<I3SRZ]`[1-QHNF\,Z*VK9G:!]QDUE&2BJ9
M@`Q#%$-^WG4WZY5*/#4L)0=B1+RY^6/2DZ:M%(YXJ6RMP9%9U2Y9>2#LR%0J
MSE&BVW'%R9*R-2N]?E*O8V"#QU'K.X:8:*,7[9)\Q50>-#JME3`"B1RG(([P
M$!V5LNK8=2\V9.)(([1#E]ENI94PZ)M+201E@<XQ.(L44C!N.*IB?'$:XAZ1
M2V"L;7HUU(OY=PT:+OG4BHFK(RCAT_=&%V]4-Q**&$`'=OW``;=5%0[5/*J'
MC-U1Q.7#9'%+3,T=.FFIQ)E`D!,G;/,XQ8^WC&B$?Z\(FL:MM=NC[23&LXR>
M1QH]GLSYLDFPIN7$!4$1BG)*<_<)<8Q_DB4(D1P@?XF%^R-N#>&^FM:G*"UU
M%P5,:P$(&\XX\IX=AB/O*6[G>:6V)`4&R7'#N3AZO"<L1Q$."R'D&&QG#P4O
M,-)!TTG+YCG';-*+2;J*HRV2KM`T*#<K$<.&J9(UG*6!%1R8HF4(W(<2$.8`
M(,S%A"K<\*:!]9&3<IXZRSB>Y)YAP9FC&&"5[7'H)TNX39,F2%(B*_>J39XN
M;3"Y8TKEGO*49(G=D5<0\BW4(9F0'#,[MA172MH,*=?U9S2<4]Q]$H5U]FM]
MR(55(FZ,E`R5WC/G.*OQ!H%TEH:K[=B.?TX9XO[K$U?J5W<WG-&9:3=<9IUR
M]R&18^A2C*I1-Q0L\IY#*XKE$SL'T4<&P<DSE("*[PV.]0W)Q!0DH;!ST)`/
M?CY,8PL]+6EMP.+2MTC(+45#NP![#A!P8FUW8^O>&LCY:@L?J0N/<187>9:"
M*@\E8'M4^I5(6M2-@:5TU/H&2)UU19HT-#G33:S)8U%NL04%#IG24`B0DDS.
M),4(`2`E(DD10N=,H:3]2N+,_P`YJ*TN6:XRNE^H5.U2L)59+&^0+\_B\A!/
M#6X/%E_Q+D=^Q6M[]Y`N`6KR\LP<E,LR650,W?M%5=5+75=$K53+*9YC8>T'
M",5;;:*XITUC:5RR.1'81(COE`U4_P!N[VP[J&1IV%E,UN,=8QQM1LR3,TYR
M(NG17U"O4':[(Q=1I2QX68!B(VFO`?H."MW+98`2'>H4Y2-?S-<Y?]N>_3CY
MX2_E"SSG];IW:\/-/RP7F)<FX`TQ:/XO.NG;23>H&HOI1>)R;C](]`K>::19
MX.TKX^FH7*;B^7Y`\K8ZU=4%(]9NG+O@1$150WH&`PJ:JLJ:U?B5*RI6S<.P
M#`0\HZ"CM[?AT;:4).<LSVDXGF8+NZY2QS*QKS'&=J&I#1<[@6[9CR+6[FWK
MEJK,#1Z4_KT=;8>R*P\A-Q\H_8&L":Q>C*Z;F(@<Y%>,I`-X-N+:6'&R4K!F
M","(TNM-O-EIU(4VH2((F".R%!5G0EHMO-I<I3&#M5^EYG=<:V3-E%K:F681
MO7KO1:RI`A943QD):KT_IUNAFUMBE7,'+KMU4VT@4$CJ&;O4VKM/4=R"0%>&
MM0VJ2"?1$ZOI.TJ45(\5"3L2L@>6<%A[;UIT0-X/&\7I1Q):J%*9JPM8,NSS
MR^1Q0R1`EHMKI54LF-LK/).=F)R(NT%-WUHH$<V%2(4;_C&RJB"[=9==67"K
MKU!52LJ`R&0'8!^^&M!:Z&VI*:-`23F<U'M)QY9<(S>'\H:2<<5+67K1QUC?
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M_=T:@_*>\>,?(79_'.^_+1X;TOH]8^1R_1S_`+N])V_@W^5?C.GX^=^-YFQ!
M&9<<KHM?'-]!OV4:,NH^6WK?3/\`:#E7E=\Z+X^J/%Q=5TW^P^S\SX<&Q!%0
MD[%X_P"\OR_!>@]2<;]_XO47Y;>;Y[>>Y^6=5^LGHIR_VS^,_<][\SZ#Z^_8
M@BQJ+T/R1ZZND](.U?,C%[O0/R/Y?^LZO"'4^%]Z_7+RK@Y/E^_\!Y5UG3_6
MZK8@@^]0_0^M-IZ[POD?(5J5ZKU"\A\(Z'RO&75>;>/?SEX7P?TIT?\`.'2<
M?3_6V((&3%7?O)Z3Y3Z^\KY'LR>#?,_Z;]Q\3XL5=3Z4^CGXOK.3VWR;U%_7
M7HNT\C[WONQ!`>Z8^U_,YD#M7/[U^YXH/4^@GF/FO3^E^G3M/<?,OU`^9S^,
MZ?I/Q/B?B'<OS.Q!&A4KM/RH^X)X]\N'1_(A@/?\F_FGI9S>PY![-YAZH?SY
MZJ[N;V7=]SXUT?=/CTVQ!#E?_(?I/_?KG=N__+GJ^I[S_J/<>A_T3HO\[V((
"_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
